QBIO - Q Biomed sees revenue ramp for Strontium89 in 2021

Commercial stage biotech company Q BioMed Inc. (QBIO) said it expects revenue from its Metastatic Bone Cancer treatment Strontium89 to ramp next year adding that it expects the treatment to be fully reimbursed by Medicare in the hospital out-patient setting. Q BioMed expects to have additional international markets available to potential patients as it continues to work through the registration of Strontium89 in multiple jurisdictions around the world, it said in a letter to shareholders. The company said it is assessing several potential clinical trial programs that may expand the indication for Strontium89 into a therapeutic use that may increase utilization in years to come. Q BioMed also said that it is developing a new drug candidate to treat young children with minimally verbal autism.

For further details see:

Q Biomed sees revenue ramp for Strontium89 in 2021